Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-04-01 Antimalarials
Drugs for malaria prophylaxis are not prescribable in NHS primary care.
Tablets can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.
Expert advice must be sought in all patients suspected to have malaria.
| Artesunate |
|
Formulary
|
Injection 60mg Available for ‘named-patient’ use from infectious disease units or specialist tropical disease centres. |
|
| Chloroquine |
|
Formulary
|
Tablets 250mg (equivalent to chloroquine base 155mg) |
 MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions |
|
|
Specialist prescribing only| Doxycycline |
|
Formulary
|
Capsules 50mg, 100mg
|
|
|
Specialist prescribing only when used for treatment of malaria| Proguanil Hydrochloride with Atovaquone |
|
Formulary
|
Tablets proguanil hydrochloride 100mg with atovaquone 250mg |
|
|
| Quinine sulphate |
|
Formulary
|
Tablets 200mg |
|
MHRA: Quinine: not to be used routinely for nocturnal leg cramps MHRA: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions |
|
|
Links
Blackpool Teaching Hospitals: Antimicrobial Formulary- BNF: Malaria, prophylaxis
- BNF: Malaria, treatment
- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- Malaria Prevention in Travellers from the UK (HPA)
- MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA: Malaria reference laboratory (Malaria RL)
- MHRA: Mefloquine may induce serious neuropsychiatric disorders (Oct 13)
- MHRA: Quinine: not to be used routinely for nocturnal leg cramps
- MHRA: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- Travel advice website (FitForTravel)
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023